Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 93-97, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engbaek, F.
Right arrow Articles by Jespersen, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engbaek, F.
Right arrow Articles by Jespersen, B.

Clinical Chemistry, Vol 35, 93-97, Copyright © 1989 by American Association for Clinical Chemistry

Enzyme immunoassay of hemoglobin A1c: analytical characteristics and clinical performance for patients with diabetes mellitus, with and without uremia

F Engbaek, SE Christensen and B Jespersen
Department of Clinical Chemistry, University Hospital of Aarhus, Denmark.

We evaluated an enzyme immunoassay (Novo BioLabs) for determination of hemoglobin A1c and measured the contribution of carbamylated hemoglobin to the hemoglobin A1c results obtained by HPLC for patients with chronic renal failure. The reference interval, determined for blood donors, was 0.035-0.050 (i.e., 3.5% to 5% of the total hemoglobin). For non-diabetic patients with chronic renal failure, on hemodialysis, the mean proportion of hemoglobin A1c was 0.038 (SD 0.0045); for umbilical cord blood it was 0.006-0.009. For diabetic patients with normal or near-normal renal function, results by enzyme immunoassay (y) and HPLC (x) correlated well (r = 0.83): y = 0.99x - 0.005. Added fetal hemoglobin or carbamylated hemoglobin did not interfere with enzyme immunoassay, but added carbamylated hemoglobin co-chromatographed with hemoglobin A1c. Measurements for patients with chronic renal failure, with or without diabetes, by enzyme immunoassay and by HPLC, were compared with measurements for patients with diabetes mellitus but no renal failure. Carbamylated hemoglobin contributed 0.019 to the hemoglobin A1c results obtained by HPLC for patients with chronic renal failure.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Am. Soc. Nephrol.Home page
V. Menon, T. Greene, A. A. Pereira, X. Wang, G. J. Beck, J. W. Kusek, A. J. Collins, A. S. Levey, and M. J. Sarnak
Glycosylated Hemoglobin and Mortality in Patients with Nondiabetic Chronic Kidney Disease
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3411 - 3417.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. P. Price
The Evolution of Immunoassay as Seen Through the Journal Clinical Chemistry
Clin. Chem., October 1, 1998; 44(10): 2071 - 2074.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.